Compare IMSR & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMSR | CAPR |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.5M | 584.9M |
| IPO Year | 2024 | 2011 |
| Metric | IMSR | CAPR |
|---|---|---|
| Price | $4.24 | $9.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $44.63 |
| AVG Volume (30 Days) | 1.1M | ★ 5.9M |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $248,357.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.14 | $2.96 |
| 52 Week High | $16.38 | $40.37 |
| Indicator | IMSR | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 35.50 | 48.78 |
| Support Level | N/A | $8.18 |
| Resistance Level | $5.69 | $11.00 |
| Average True Range (ATR) | 0.27 | 0.69 |
| MACD | -0.10 | 0.22 |
| Stochastic Oscillator | 4.35 | 29.57 |
Terrestrial Energy Inc is a technology company engaged in the development and commercialization of nuclear power plants. The company is focused on its proprietary Integral Molten Salt Reactor (IMSR) technology, a Generation IV reactor design intended to produce reliable, emission-free energy in the form of electricity and high-temperature heat for industrial applications. Its activities mainly involve advancing the design, licensing, and deployment of IMSR plants for commercial energy generation.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.